Needed: Critical thinking about psychiatric medications

Social Work in Mental Health

Volumn 7, Issue 1-3, 2009, Pages 42-61

  Cohen, David ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Conflicts of interest; Pharmaceutical industry; Psychopharmacology; Publication bias; Substance use

Indexed keywords

EID: 61449229293     PISSN: 15332985     EISSN: 15332993     Source Type: Journal    
DOI: 10.1080/15332980802072371     Document Type: Conference Paper

References (78)

1. Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist, 58, 1028-1043.
2. Armstrong, D., & Mathews, A. W. (2004, May 14). Pfizer case signals tougher action on off-label drug use. Wall Street Journal, p. B1.
3. Austrian, S. G. (2000). Mental disorders, medications, and clinical social work (2nd edition). New York: Columbia University Press.
4. Bentley, K. J. (2003). (Ed.). Psychiatric medication issues for social workers, counselors, and psychologists [Special Issue]. Social Work in Mental Health, 1 (4).
5. Bentley, K. J., & Walsh, J. (2001). The social worker and psychotropic medication: Toward effective collaboration between mental health clients, families, and providers (2nd edition). Boston: Wadsworth Publishing.
6. Bentley, K. J., Walsh, J., & Farmer, R. (2005). Referring clients for psychiatric medication: Best practices for social workers. Best Practices in Mental Health, 1 (1), 59-71.
7. Braslow, J. (1997). Mental ills and bodily cures: Psychiatric treatment in the first half of the twentieth century. Berkeley: University of California Press.
8. Breggin, P.R., & Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Cambridge, MA: Perseus.
9. Cauchon, D. (2000, September 25). FDA advisors tied to industry. USA Today, pp. 1A, 10A.
10. Chalmers, I. (1990). Underreporting research is scientific misconduct. JAMA, 263, 1405-1408.
11. Cohen, D. (1997a). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher & R. G. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 173-228). New York: Wiley.
12. Cohen, D. (1997b). Psychiatrogenics: Introducing chlorpromazine in psychiatry. Review of Existential Psychology and Psychiatry, 23 (1-2), 206-233.
13. Cohen, D. (2003). The psychiatric medication history: Context, purpose, and method. Social Work in Mental Health, 4, 5-28.
14. Cohen, D. (2005). Clinical psychopharmacology trials: "Gold standard" or "fool's gold"? In S. Kirk (ed.), Mental disorders in the social environment: Perspectives from social work (pp. 347-367). New York: Columbia University Press.
15. Cohen, D., & Karsenty, S. (1998). Représentations sociales des effets secondaires des anxiolytiques: Une étude comparative Québec-France. [Social representations of the side effects of anxiolytic drugs: A comparative Quebec-France study]. Research report submitted to Ministry of Health & Municipal Affairs, France.
16. Cohen, D., McCubbin, M., Collin, J., & Perodeau, G. (2001). Medications as social phenomena. Health, 5, 441-469.
17. Conrad, P., & Schneider, J. (1992). Deviance and medicalization: From badness to sickness (2nd ed.). Philadelphia, PA: Temple University Press.
18. Depressing research. (2004). Lancet, 363, 1335.
19. Diekelmann, N. L., & Kavanagh, K H. (Eds.). (2002). First, do no harm: Power, oppression, and violence in healthcare. Madison, WI: University of Wisconsin Press.
20. Dolnick, E. (1998). Madness on the couch: Blaming the victim in the heyday of psychoanalysis. New York: Simon & Schuster.
21. Dziegielewski, S. F., & Leon, A. M. (2001). Social work practice and psychopharmacology. New York: Springer Publishing Company.
22. Fancher, R. (1995). Cultures of healing: Correcting the image of American mental health care. San Francisco: Freeman.
23. Farmer, R., & Bentley, K. J. (2002). Social workers as medication facilitators. In K. J. Bentley (Ed.), Social work practice in mental health: Contemporary roles, tasks, and techniques (pp. 211-229). Pacific Grove, CA: Brooks/Cole.
24. Fava, (2004). Conflict of interest in psychopharmacology: Can Dr. Jekyll still control Mr. Hyde? Psychotherapy & Psychosomatics, 73, 1-4.
25. Floersch, J. (2002). Meds, money, and manners: The case management of severe mental illness. New York: Columbia University Press.
26. Fortune. (2000). How the industries stack up. Available from http://money.cnn.com/ magazines/fortune-archive/2000/04/17/278092/index.htm
27. Fukuyama, F. (2002). Our posthuman future: Consequences of the biotechnology revolution. New York: Farrar, Straus, and Giroux.
28. Gibbs, L., & Gambrill, E. (1999). Critical thinking for social workers: Exercises for the helping professions. Thousand Oaks, CA: Pine Forge Press.
29. Grinspoon, L., & Hedblom, P. (1975). The speed culture: Amphetamine use and abuse in America. Cambridge, MA: Harvard University Press.
30. Harris, G. (2003, August 7). Debate resumes over the safety of depression's wonder drugs. New York Times, p. A1.
31. Harris, G. (2004a, June 3). Spitzer sues a drug maker, saying it hid negative data. New York Times, pp. A1, C4.
32. Harris, G. (2004b, April 16). Expert kept from speaking at antidepressant hearing. New York Times, p. A-16.
33. Healy, D. (1997). The antidepressant era. New York: Harvard University Press.
34. Healy, D. (2002). The creation of psychopharmacology. New York: Harvard University Press.
35. Hegarty, J. D., Baldessarini, R. J., Tohen, M., Waternaux, C., & Oepen, G. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
36. Hoehn-Saric, R., Lipsey, J. R., & McLeod, D. A. (1990). Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology, 10, 343-345.
37. Horton, R. (2004). The dawn of Mcscience. New York Review of Books, 51(4). Retrieved April 4, 2004 from http://www.nybooks.com/articles
38. Illich, I. (1976). Limits to medicine. Medical nemesis: The expropriation of health. Toronto: McClelland and Stewart Limited.
39. IMS Health. (2003, February 28). 2002 world pharma sales growth: Slower, but still healthy. Retrieved June 16, 2003 from http://www.ims-global.com/ insight/news-story/0302/news-story-030228.htm
40. Jacobs, D., & Cohen, D. (1999). What is really known about psychological alterations produced by psychiatric drugs? International Journal of Risk and Safety in Medicine, 12, 37-47.
41. Judge: Paxil ads "misleading." (2002, August 21). CBS News. Retrieved April 15, 2004 from http://www.cbsnews.com/stories/2002/08/ 20/health/main519266.shtml
42. Johnson, A. B. (1990). Out of Bedlam: The truth about deinstitutionalization. New York: Basic Books.
43. Johnson, L. A. (2004, May 17). Behavior drug spending eclipses other youth meds. The Standard Times. Retrieved May 17, 2004 from http://www.southcoasttoday.com/daily/05-04/05-17-04/a05wn.htm
44. Jureidini, J. N., Doecke, C. J., Mansfield, P.R., Haby, M.M., Menkes, D. B., & Tonkin, A.L. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal, 328, 879-883.
45. Kessler, R. A., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikanga, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication. JAMA, 289, 3095-3105.
46. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S.N. (2002). The Emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5, article 23. Available at http://journals.apa.org/prevention/volume5/toc-jul15- 02.htm
47. Kondro W., & Sibbald, B. (2004). Drug company experts advised staff to withhold data about SSRI use in children: A 1993-1996 industry study showed that paroxetine was no more effective than placebo in treating pediatric depression. Canadian Medical Association Journal, 170, 783.
48. Kranish, M. (2002, December 22). FDA counsel's rise embodies US shift. Boston Globe. Retrieved April 16 2004 from http://www.bostonglobe.com
49. Lacasse, J.F., & Gomory, T. (2003). Is graduate social work education promoting a critical approach to mental health practice? Journal of Social Work Education, 39, 383-408.
50. Meier, B. (2004, June 21). A medical journal quandary: Jow to report on drug trials. New York Times, p. A-1.
51. Medawar, C., & Hardon, A. (2004). Medicines out of control? Antidepressants and the conspiracy of goodwill. London: Aksant Academic Publishers/Transaction.
52. Mental health: A report from the Surgeon General. (1999). Washington: Office of the Surgeon General.
53. Mirowsky, J., & Ross, C. E. (2003). Social causes of psychological distress (2nd ed.). Chicago: Aldine de Gruyter.
54. Moncrieff, J., & Cohen, D. (2005). Rethinking models of psychotropic drug action. Psychotherapy & Psychosomatics, 73, 145-153.
55. Morgan, R.F. (Ed.). (1983). The iatrogenics handbook: A critical look at research and practice in the helping professions. Toronto: IPI Publishing.
56. National Center for Health Statistics. (2005). Health United States, 2004. Retrieved February 15, 2005 from http://www.cdc.gov/nchs/hus.htm
57. Nesse, R. M., & Berridge, K. C. (1997). Psychoactive drug use in evolutionary perspective. Science, 278 (5335), 63-66.
58. New 2001 data shows big drug companies spent almost two-and-one-half times as much on marketing, advertising, and administration as they spent on research and development. (2002). FamiliesUSA. Retrieved June 5, 2004 from: http://www.familiesusa.org/site/PageServer?pagename=new2001data
59. Patten, S. B. (2004). The impact of population treatment on population health: Synthesis of data from two national sources in Canada. Population Health Metrics, 2 (9). Available online: http://www.pophealthmetrics.com/ content/2/1/9
60. Peterson, (2004, February 1). Making drugs, shaping the rules. New York Times, p. A1.
61. Procyshin, R. M., Chan, A., Fortin, P., & Jenkins, W. (2004). Prevalence and outcome of pharmaceutical industry - sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry, 49 (9), 601-606.
62. Relman, A. S., & Angell, M. (2002, December 16). America's other drug problem: How the drug industry disorts medicine and politics. The New Republic, pp. 27-41.
63. Research Triangle Institute. (2002). Screening for depression: Systematic evidence review. Rockville, MD: Agency for Health Care Quality and Research.
64. Sharav, V. H. (2004). Conflicts of interests policy-New York Times. Alliance for Human Research Protection. Available at: http://www.ahrp.org/infomail/04/03/28.html
65. Sharav, V. H. (2003). Children in clinical research: A conflict of moral values. American Journal of Bioethics, InFocus, pp. 1-81. Retrieved May 7, 2003 from http://bioethics.net
66. Shogren, E. (2004). FDA sat on report linking suicide, drugs. Los Angeles Times. Retrieved April 6, 2004 from http://www.latimes.com/news/ nationworld/nation/la-nasuicide6apr06,1,2908070. story?coll=la-headlines-nation
67. Smith, D. C. (2001). On the incompatibility of the biological and empathic-relational model. Ethical Human Sciences and Services, 3, 47-52.
68. Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies, PLoS Medicine, 2 (5), e138.
69. Sullivan, R. J., & Hagen, E. H. (2002). Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction, 97, 389-400.
70. Szasz, T. (1974). Ceremonial chemistry: The ritual persecution of drugs, addicts, and pushers. New York: Anchor Press/Doubleday.
71. Van Praag, H. M. (2002). Why has the antidepressant era not shown a significant drop in suicide rates? Crisis, 23, 77-82.
72. Vastag, B. (2001). Pay attention: Ritalin acts much like cocaine. JAMA, 286, 905-906.
73. Wagner, K. D., Robb, A. S., Findling, R. L., Jin, J., Gutierrez, M. M., & Heydorn, W. E. (2004). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry, 161, 1079-1083.
74. Walsh, J., Farmer, R., Taylor, M., & Bentley, K. J. (2003). Ethical dilemmas of practicing social workers around psychiatric medication: Results of a national study. Social Work in Mental health, 1 (4), 91-105.
75. Waters, R. (2004, April 16). FDA was urged to limit kids' antidepressants. Advice citing risk of suicide rejected. San Francisco Chronicle, p. A-1.
76. Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge, MA: Perseus.
77. Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet, 363, 1341-1345.
78. Wilman, D. (2004, April 9). Curbs on outside deals at NIH urged. Los Angeles Times. Retrieved April 15, 2004 from http://latimes.com/la-na- nihapr09,1,1273370.story